Oral Fludrocortisone Test for Salt-Sensitive Screening in Hypertensive Patients: A Randomized Crossover Trial
- PMID: 30581606
- PMCID: PMC6276467
- DOI: 10.1155/2018/7437858
Oral Fludrocortisone Test for Salt-Sensitive Screening in Hypertensive Patients: A Randomized Crossover Trial
Abstract
Background: Salt sensitivity is associated with an increased cardiovascular risk, but the gold standard method (diet cycles) requires 24-h urine samples and has poor patient compliance.
Objectives: Test the hypothesis that oral fludrocortisone (0.4 mg per day for 7 days) is a good alternative in identifying salt-sensitive patients.
Methodology: We conducted a randomized crossover study with 30 hypertensive individuals comprising the following steps: (1) washout; (2) phase A (low- and high-sodium diet cycles); (3) washout 2; (4) phase B (fludrocortisone test). Phase A and B steps were performed in a random way. Consistent with the literature, we found that 53.3% were salt-sensitive according to the reference test. Using the ROC curve, the fludrocortisone test defined salt sensitivity by a median blood pressure increase of ≥3 mmHg. A good accuracy of fludrocortisone in detecting salt sensitivity was observed (AUC: 0.732±0.065; p<0.001), with 80% sensitivity and 53% specificity.
Conclusion: The fludrocortisone test is a good option for screening salt sensitivity in hypertensive patients. However, the low specificity prevents this test from being an ideal substitute to the labor-intensive diet cycles exam in the definition of salt sensitivity. This clinical trial is registered with NCT01453959.
Figures
Similar articles
-
Safety and Efficacy of Fludrocortisone in the Treatment of Cerebral Salt Wasting in Patients With Tuberculous Meningitis: A Randomized Clinical Trial.JAMA Neurol. 2018 Nov 1;75(11):1383-1391. doi: 10.1001/jamaneurol.2018.2178. JAMA Neurol. 2018. PMID: 30105362 Free PMC article. Clinical Trial.
-
Moderate salt restriction with or without paricalcitol in type 2 diabetes and losartan-resistant macroalbuminuria (PROCEED): a randomised, double-blind, placebo-controlled, crossover trial.Lancet Diabetes Endocrinol. 2018 Jan;6(1):27-40. doi: 10.1016/S2213-8587(17)30359-5. Epub 2017 Nov 2. Lancet Diabetes Endocrinol. 2018. PMID: 29104158 Clinical Trial.
-
Adverse cardiac effects of salt with fludrocortisone in hypertension.Hypertension. 2001 Mar;37(3):856-61. doi: 10.1161/01.hyp.37.3.856. Hypertension. 2001. PMID: 11244008 Clinical Trial.
-
[Changes in calcium levels in blood and urine during various regimens of table salt intake in patients with essential arterial hypertension].Srp Arh Celok Lek. 2002 Jan-Feb;130(1-2):7-12. doi: 10.2298/sarh0202007t. Srp Arh Celok Lek. 2002. PMID: 12073292 Clinical Trial. Serbian.
-
Impact of Salt Intake on the Pathogenesis and Treatment of Hypertension.Adv Exp Med Biol. 2017;956:61-84. doi: 10.1007/5584_2016_147. Adv Exp Med Biol. 2017. PMID: 27757935 Review.
References
-
- Weinberger M. H., Miller J. Z., Luft F. C., Grim C. E., Fineberg N. S. Definitions and characteristics of sodium sensitivity and blood pressure resistance. Hypertension. 1986;8(6):127–II-134. - PubMed
Associated data
LinkOut - more resources
Full Text Sources
Medical